Ocuphire Pharma Results Presentation Deck
October 2022, 53 slides
  1. Ocuphire Pharma
  2. Results Presentation Decks
event | Ocuphire Pharma
disclosures and forward looking statements | Ocuphire Pharma
event agenda speakers time | Ocuphire Pharma
event agenda speakers tufts cage | Ocuphire Pharma
company overview | Ocuphire Pharma
| Ocuphire Pharma
overview refractive retina crag positive data ped | Ocuphire Pharma
track record of achieving milestones | Ocuphire Pharma
disease of diabetic | Ocuphire Pharma
diabetic eye disease is common cause of blindness | Ocuphire Pharma
diabetes is a growing global health epidemic | Ocuphire Pharma
diabetic patients usually present with complex morbidities | Ocuphire Pharma
global prevalence of diabetes associated retinal disease arn | Ocuphire Pharma
measuring the severity of diabetic | Ocuphire Pharma
predicts vision threatening complications | Ocuphire Pharma
vision loss is concern of diabetic patients what are the top concerns for diabetic patients amputation losing a other eye problems foot kidney | Ocuphire Pharma
early management of diabetic medical and management is first line of treatment | Ocuphire Pharma
majority of physicians use a wait and monitor approach for patients | Ocuphire Pharma
diabetic at a glance | Ocuphire Pharma
current treatment landscape | Ocuphire Pharma
anti therapies are standard of care for focused on and local delivery have demonstrated me and a | Ocuphire Pharma
panorama study further emphasizes need for treatment of sham | Ocuphire Pharma
preferred practice pattern reveals high unmet need in mild moderate and severe patients normal or minimal no no no no no sometimes rarely an oral option treatment options across all stages no no usually | Ocuphire Pharma
current conventional treatment is challenging for patients other medical or physical condition other incidental obligations mean min are generally | Ocuphire Pharma
multiple targets in treatment landscape | Ocuphire Pharma
injections landscape patients | Ocuphire Pharma
topical eyedrops in clinical development for | Ocuphire Pharma
oral treatments in clinical development | Ocuphire Pharma
is different than past oral failures in retina | Ocuphire Pharma
opportunities for new therapies in retina | Ocuphire Pharma
paradigm shift oral treatment option | Ocuphire Pharma
novel and dual acting in an oral pill ref ref | Ocuphire Pharma
in validation of mechanism of action | Ocuphire Pharma
effects in normal cells we | Ocuphire Pharma
preclinical enabling studies | Ocuphire Pharma
preclinical data oral blocks | Ocuphire Pharma
summary of prior clinical trials extensively studied in clinical trials across phase and phase by and | Ocuphire Pharma
phase clinical trials data supporting the zeta trial a | Ocuphire Pharma
safety summary from phase and phase trials | Ocuphire Pharma
zeta phase trial in diabetic | Ocuphire Pharma
zeta phase design for day bid placebo bid top line data expected in labs | Ocuphire Pharma
key eligibility criteria in zeta | Ocuphire Pharma
why is an important diabetic severity scale | Ocuphire Pharma
zeta trial demographics and masked safety data | Ocuphire Pharma
characteristics for zeta trial | Ocuphire Pharma
characteristics for zeta trial continued | Ocuphire Pharma
characteristics for zeta trial continued | Ocuphire Pharma
comprehensive laboratory panels collected in zeta | Ocuphire Pharma
masked safety findings from ongoing zeta trial oral safety profile consistent with that seen in prior trials subjects | Ocuphire Pharma
product candidate profile for multiple retinal indications | Ocuphire Pharma
zeta trial design and data expectations | Ocuphire Pharma
has the potential to be first line of therapy for patients efficacy signal safety non invasive treatment option guidance physician patients efficacy signal safety non invasive treatment option | Ocuphire Pharma
is positioned to fulfill a significant unmet need in diabetic eye disease | Ocuphire Pharma
See More
Ocuphire Pharma
Results Presentation Decks
Explore Topics
Blood
Clinical trial
Recent decks by Ocuphire Pharma
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
See all presentations by Ocuphire Pharma (10 decks)
Recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io